Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sells completed at $.30. Not a big profit, but I'm pretty sure I can buy them back for $.20 down the road. And with a market that has no clue where it's going from one day to the next, taking profits needs to be "job 1".
Ding ding ding! If that’s your situation.
The usual. we issued 1,630,191 Commitment Shares to Lincoln Park as a fee for its commitment to purchase shares of our Common stock under the Purchase Agreement
$326k @ $0.20
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=116859913&type=HTML&symbol=KTRA&companyName=Kintara+Therapeutics+Inc.&formType=424B5&formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&dateFiled=2022-08-03&CK=1498382#lincoln_park_transaction
Well- I have been just riding it. However- the position is overall green, With today's exuberance- I really am thinking about selling because I absolutely know I can buy it back for less shortly. Also- they will have to do an RS and I'd rather buy it afterwards than hold through it.
In a case where it’s significantly upside down here and a truly long investment you mostly just ride it ‘cause there’s little to recoup and all to gain eventually. For me you know the story just like Gillian’s Island I was only looking for a three hour tour that went south.
If I remember Lincoln would have an upfront commitment fee and then some formula for a significant discount for the stock put to them based on prior 30 day average pps Blah Blah Blah or that was another terrible financing term I’ve seen before lol.
Totally agree, That's why my comment was "I guess" it counts as a catalyst. I would be more likely to sell on that announcement- certainly wouldn't buy.
Funny I missed the open and $0.40 with my rambling reply. Instantly sold the 7,700 remaining at market $0.32 for +$010 each. Will buy it back someday I figure it’s teens bound as this soaks in.
Whew let’s hope that were true. Let me just say anything is possible,, but lol. There’s a significant cost to ktra for Lincoln to commit to this kind of equity line agreement. Details should come in the 8k or 10q attachments. First hand witnessed one company battle out of this same boilerplate agreement and get less outrageous but still outraged financing. Someone at Torrey Hills Capital years back rated Lincoln lower than pond scum and they deal with every and all types of financiers.
Still find it odd they can’t strike a contingent deal with any bio/pharma for $15-30 million to see them through if the drip is so sure fire as it appears to be by the presentation progress reports. Not my area of expertise just odd to me.
KTRA doubled but isn't it just fancy words for a tidy dilution with firewall for investor?
I guess this counts as an upside catalyst.........
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
August 03 2022 - 08:30AM
PR Newswire (US)
Alert
Print
Share On Facebook
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) (Kintara or the Company), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.
Under the terms of and subject to satisfaction of the conditions contained in the agreement, Kintara will have the right in its sole discretion, but not the obligation, to sell to LPC up to $20 million worth of shares of its common stock from time to time over the 36-month term of the agreement. Kintara controls the timing and amount of any future sales of its shares of common stock and LPC is obligated to make purchases in accordance with the terms of the purchase agreement, subject to various limitations contained in the agreement, including those under the Nasdaq listing rules. Any common stock that is sold by Kintara to LPC under the agreement will occur at a purchase price that is based on the market prices prevailing at the time of each sale to LPC. There is no upper limit to the price per share that LPC may pay for future stock issuances under the purchase agreement, and LPC has agreed not to cause or engage in any direct or indirect short selling or hedging of Kintara's common stock. No warrants are being issued in this transaction and the purchase agreement does not contain any rights of first refusal, participation rights, penalties or liquidated damages provisions in favor of any party. Kintara may terminate the purchase agreement at any time, at its sole discretion, without any cost or penalty.
The Company expects this commitment from LPC will provide financial flexibility and is aligned with Kintara's long-term strategy for value creation. Kintara intends to use any net proceeds from the sale of its common stock to LPC for working capital and general corporate purposes, including development expenses for VAL-083 and REM-001.
"We are excited to enter into this transaction with Lincoln Park Capital and believe that this agreement provides us an opportunity to access capital in a very efficient manner," said Robert E. Hoffman, President and Chief Executive Officer of Kintara. "We believe that the financial flexibility provided by this agreement will further support our clinical development efforts with VAL-083 in glioblastoma and REM-001 in cutaneous metastatic breast cancer."
Additional information regarding the purchase agreement is set forth in a Current Report on Form 8-K, which Kintara will file with the Securities and Exchange Commission (SEC).
The securities described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-254662) filed with the SEC on March 24, 2021 and declared effective on April 1, 2021. The offering of the securities described herein will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by request from Kintara Therapeutics at 9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121 or at (858) 350-4364.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received
Thanks , anyone expecting some substantial changes in due time ? the chart ist just one point. I think there´s nothin positive to expect....
In this for 1 year now. Chart tells me nothin good.
Let me know i you expect any positve changes in due time...
HD
Maybe I could just pretend I don't own any.........
RSI 30 oversold is like a lunar gravitational pull for this stock. No matter the upside bounce it will revert to dropping in price until it skates along the rsi 30 while people load up thinking this must be the bottom. So far good for a swing trade but mostly a value trap. Then there’s the Nasdaq $1 minimum on the table because they need to be preparing soon to execute the reverse split and maintain compliance. If there’s no upside catalyst to coincide with that shorts and market makers will fill every bid short until it’s back to pre-split levels. It only happens every time when there are no developments to mitigate the pre-split sentiment towards the stock.
Lol well yes and no. After putting in the low it looked like there was good interest in moving it up but then at .34 it turned out the 2 year trend prevailed,, any up move is just a dead cat bounce before going lower. Hopefully they say something that disrupts the trend one day.
After capitulating here I moved to hiru and got lucky to be up 89% so far. Puts me within $5k of making up losses. Figure if that continues up I’ll look to move a little back here because I’m stubborn lol.
What a surprise, yes?
Too bad they can't manage their stock aw well as the do their presentations.
I will continue to hang out to see if this drug can get approved.
This charts like it’s going below the $0.1406 low. Especially with earnings coming only to show cash burn and less cash on hand. Down to 7,700 in Robinhood at $0.22 that I didn’t take out at .34 lol. Guess I’ll hold those hero or zero!
Not much going on here so far
Well hopefully it’s Friday traders selling out and they pick back up next week moving higher.
A perfect Trifecta of cancer stocks is rising. KTRA, CVM, and NWBO, all moving on drug news. In all 3 now, the sky is the limit, and no limit of combo trials coming down the pike. GLTA!
I'm watching. I'm also perfectly fine if I don't get out. The "test buys" only added up to a few thousand shares, so if they decide to pull up a lawn chair and stay put- it's ok.
10 minutes to get you out. Close call at rsi 70.41 overbought and might roll over here.
I'm cheering for your hunch.
Was a good day all around. Only one of my stocks that wasn't green was the Gold Miner and that was totally to be expected.
A good day and close. Good to hear that you’ve lowered your average. This has actually begun to trade as expected of the bottom. Looking at the fact that the one year high is $2.85 which was a meme run I guess. Since the FDA fast track 45 million share day I’ve had a feeling this is going to be walked back north a good little bit. Just a hunch.
Well- that would work. Whenever they get sold, it will make my cost basis for the core position look much better. That'll be helpful down the road. Whenever the patients start getting the drug.
If they hold it around .30 and consolidate you’ll be out in the first hour of the next good day whether it’s Friday or next week.
Think I'll put in a sell order for all of those small lots at $.35. If they sell, fine, it will be a nice profit. If not- no worries. Leaving the core position alone.
Yes I’m up over 40% on the .22’s where it’s trading now which is quite the win in these markets and yet hard pressed to just sell on principle when rolling the dice could be very lucrative with this one. Not actually expecting another flash run to $0.84 but knowing it can happen keeps my attention lol.
Some context to RSI it’s necessary to figure out what timeframe the market is using to drive the big sell off. On a one day one minute chart you can see the oscillation of buy/sell tiggers at 30 and 70 but it’s maybe the one month timeframe that would guide an rsi of 70-80 to begin the sell off cooling unless it was trading sky high because of news.
it's always good to have a sketched in exit plan. Funny- a lot of those little "what are the MMs actually doing" buys are now quite green. I considered selling some of them to bring my cost basis down further, but haven't set up any sell order yet.
Started looking at $0.37 but it’s hard to say if the hype keeps it going higher. Right now the RSI (relative strength index) is exactly at 70 and that’s the threshold for overbought which can mean a sell off coming but it looks to be cooling here and maybe setting up for another leg up later or Friday? RSI 80 would likely trigger me to sell and see how far it drops to cool off before getting back in because it feels like traders are trying to get this higher.
Normally I’d just go long on a good prospect like this but you know how that worked for me from $0.98 so I’m just trying to grind $3 & $6k here or there to feel better and beat the boredom just waiting to hopefully break even.
Be great if they hit a nice news item while there’s a lot of interest now. Wishful lol.
Have you a target to take your next profits yet?
Looking for $0.37 next major resistance.
Yes I went in 68k @ $0.217. Trading and chart just looks strong here is my hunch. Really only gained $0.03 a share dancing around because I wasn’t slick enough to get the .20’s at the close Friday and premarket Tuesday.
From a guy on stocktwits that listened in fwiw,,,hopefully they pull a rabbit out of the hat or r/s it is.
“I asked about potential options for increasing shareholder value/Nasdaq compliance. Their response was that they announced Fast Track designation, looking at other potential FDA Designations, and looking to announce REM-001 trial which will be open label so they'd be able to provide regular updates for that trial. They are also trying to arrange partnerships/non-dilutive capital raises. They also stated they're keeping track of the Nasdaq compliance and will eventually have to consider a reverse split as they're getting close to the compliance deadline. Stated that a hard part is capital markets have been difficult and big pharma in general is still holding off on using all the capital they have.”
Normal volume- decent trading. We'll see what tomorrow brings.
Ouch. What happened to the volume
Lol. Reverse split is next
Lol transient comes in four day increments otherwise she’d have to admit inflation was real. I really miss the Greenspan green-speak and barbiturates Bernanke days.
Maybe also the feds will learn to look further ahead than the next 4 days. But I'm not counting on it.
That’s good. It beats the boredom and it’s been a tough market for any style when the bull flips to bear and you’re at the down 20% tipping point between bear correction versus full on bear market. It’s only half way down if it’s going full bear I figure. My roses case is big money funds don’t want to crash and lose a decade of gains and will support things at this level while rotating out of tech and into consumer and bio while waiting until November when Congress flips and takes away biden’s checkbook. Could happen as the economy is not that bad and Feds seem to get it finally with rate hikes and drawing down their balance sheet etc.
I am reviving my short term swing trade skills. It's not my favorite trading method, but IF we go into recession, it's one I need to keep things balanced. I use a parlay type trade so that keeps it interesting, at least.
Yes thanks I’m going to ride the boards until next week.I’m looking at the support and beginning to wonder if the recent 45 million share day on the fast track news actually moved the float into stronger hands building a base? There’s less than 65 million actually in the trade-able float so it’s a possibility but the kind that can get you bagged just as easily in this one over the two year chart.
I’m trying to build a case to get back in make-up losses and possibly catch a nice run that could be coming lol.
Hopefully next week it breaks one way or the other and I can go all in lol.
Still has a high volume this morning. I'd be sitting quietly too- I don't like to buy things going into a long weekend.
Still fence sitting in cash watching it creep up. Still concerned they drop it and close the gap open at the least.
We’ll shockingly I didn’t get burned getting out at .25 and now if I can 1) get in before it goes back up and 2) not get in too high like I have each time before lol.
LOL! Looking through the rose colored glasses then- we could say it's over-performing!
I’ve also been trying to wrap my head around it’s really a $0.02 stock with 650,000,000 outstanding with potential if you consider the 1-10 reverse split in 2019 under Delmar.
There will be a point where ktra investors make money it’s left to be seen to what degree early investors will profit depending on dilution and reverse splits etc. When it succeeds.
DJIA returning to down under 30,000 now. I have had a 29,500 target for the come to Jesus moment when it either bounces off that technical level and doesn’t look back or collapses and we go full bear market with the bottom tbd. We’re one bad day away from it happening.
It's not a fun stock to own. However- as noted before- I'm just here for the drug which is so needed. It would be nice to make some money on it, but I have other stocks which will do a better job of that. At least at some point. Market's down over 500 points PM so I'm not expecting that today will actually be profitable for me. Sigh............
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1415
|
Created
|
01/25/13
|
Type
|
Free
|
Moderators |
https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.
11/03/21
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |